3D Global Biotech Inc. (TPEX: 6808)
Health Care · Biotechnology · TW
NT$37.00
-3.01% today · -8.2% 1Y
3D Global Biotech Inc. (TPEX: 6808) operates in the Biotechnology industry within the Health Care sector. The company is valued at $89.02M and employs 43 people.
Over the last twelve months the share price has lost 8.2%, trading between 22.45 and 63.00.
Tweenvest scores 3D Global Biotech Inc. across four factors: quality 66/100, value 20/100, growth 88/100, dividend 24/100. Its strongest factor is growth.
6808 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $89.02M
- Revenue (TTM)
- $5.00M
- P/E
- 205.84
- EPS
- 0.18
- Dividend yield
- 0.27%
- Beta (5Y)
- 0.14
- 52-week high
- NT$63.00
- 52-week low
- NT$22.45
- Avg volume (3M)
- —
- Shares outstanding
- 76.98M
- Employees
- 43
- Next earnings
- —
About 3D Global Biotech Inc.
Based in New Taipei City, China, 3D Global Biotech Inc. (3DGBI) specializes in the development of advanced medical materials designed for human body reconstruction. The company leverages sophisticated cell culture systems, cutting-edge 3D printing technology, and proprietary bio-inks hydrogel to create personalized, patient-specific cell-based medical products. Beyond product manufacturing, 3DGBI is dedicated to building platforms for human tissue and organ regeneration, engineering customized medical equipment, and undertaking significant professional research. Its extensive product range includes artificial bone substitutes, skull fixation systems, biological dressings, bio-inks, and bioprinting machinery. They also offer specialized solutions for orthopedic, dental, cranial, and scalp reconstruction. The company serves a broad spectrum of clients, including medical centers, research institutions, businesses, and distributors. 3DGBI actively fosters an interdisciplinary alliance, bringing together expertise from industry, government, academia, research, and medicine. It was established in 2014.
- ISIN
- TW0006808009
- Founded
- 2014
- Listed since
- Dec 25, 2020
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.09 | -0.46% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.